Related Experiment Video
Updated: Sep 10, 2025
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Structure-based drug design of small molecule AKT1 inhibitors to treat glioma
Xiuzhi Jia1,2, Qinglian Han3, Xiaoqun Ma4
1Department of Immunology and Pathogen Biology, College of Medicine, Lishui University, Lishui, 323000, Zhejiang, China.
Abstract:
The highly aggressive primary brain tumor, glioma, presents significant therapeutic challenges, particularly in its diffuse form, which remains resistant to curative treatment even after surgical intervention. Conventional approaches such as surgery, radiotherapy, and chemotherapy often fail to achieve satisfactory outcomes, underscoring the urgent need for more effective targeted therapies. In this study, we have developed novel AKT inhibitors-compounds 3260-0411, V012-5231, and V016-4965. These compounds demonstrate a substantial reduction in both AKT protein and mRNA levels in U251 and T98G glioma cells. Furthermore, our in vitro experiments reveal that these inhibitors effectively suppress AKT1 enzyme activity and induce apoptosis in glioma cells. Molecular dynamics simulations indicate that all three compounds exhibit excellent dynamic stability when bound to AKT; notably V016-4965 demonstrates the highest binding stability among them. Collectively, our findings suggest that compounds 3260-0411, V012-5231, and V016-4965 hold great promise as targeted therapies against AKT for treating glioma-a challenging malignancy with limited management options.
Insights
Novel AKT inhibitors show promise for treating aggressive glioma. These compounds effectively reduce AKT levels and induce cancer cell death, offering a potential new targeted therapy for this challenging brain tumor.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Glioma is an aggressive brain tumor with limited treatment options.
- Current therapies like surgery, radiotherapy, and chemotherapy are often ineffective against diffuse glioma.
- There is a critical need for novel, targeted therapeutic strategies for glioma treatment.
Purpose of the Study:
- To develop and evaluate novel AKT inhibitors for glioma treatment.
- To assess the efficacy of compounds 3260-0411, V012-5231, and V016-4965 in inhibiting AKT signaling in glioma cells.
- To investigate the potential of these inhibitors as targeted therapies for glioma.
Main Methods:
- Synthesis and characterization of novel AKT inhibitors (compounds 3260-0411, V012-5231, V016-4965).
- In vitro studies using U251 and T98G glioma cell lines to assess AKT protein and mRNA levels, AKT1 enzyme activity, and apoptosis induction.
- Molecular dynamics simulations to evaluate the binding stability of the inhibitors with AKT.
Main Results:
- Compounds 3260-0411, V012-5231, and V016-4965 significantly reduced AKT protein and mRNA levels in glioma cells.
- These inhibitors effectively suppressed AKT1 enzyme activity and induced apoptosis in vitro.
- Molecular dynamics simulations confirmed the dynamic stability of the compounds bound to AKT, with V016-4965 showing the highest stability.
Conclusions:
- The novel AKT inhibitors (3260-0411, V012-5231, V016-4965) demonstrate significant anti-glioma activity.
- These compounds represent promising targeted therapeutic agents against AKT for glioma treatment.
- Further investigation is warranted to explore the clinical potential of these AKT inhibitors in managing glioma.
More Related Videos
09:24Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
Published on: June 9, 2016
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
